| 產(chǎn)品編號 | bs-20173R |
| 英文名稱 | GLUT1 Rabbit pAb |
| 中文名稱 | 葡萄糖轉(zhuǎn)運蛋白1抗體 |
| 別 名 | Glucose Transporter GLUT1; GT-1; GLUT-1; GLUT 1; Solute carrier family 2; facilitated glucose transporter member 1; Glucose transporter type 1; erythrocyte/brain; DYT17; DYT18; Erythrocyte/brain HepG2 glucose transporter; Erythrocyte/hepatoma glucose transporter; Glucose transporter 1; Glucose transporter type 1; Glucose transporter type 1 erythrocyte/brain; Glucose transporter type 1, erythrocyte/brain; GLUT; GLUT1; GLUT1DS; GLUTB; GT1; GTG1; Gtg3; GTR1_HUMAN; HepG2 glucose transporter; MGC141895; MGC141896; PED; RATGTG1; SLC2A 1; SLC2A1; Solute carrier family 2(facilitated glucose transporter), member 1; Solute carrier family 2 facilitated glucose transporter member 1. |
 |
Specific References (6) | bs-20173R has been referenced in 6 publications.
[IF=5.62] Ying-Ying Yang. et al. The human islet amyloid polypeptide reduces hippocampal tauopathy and behavioral impairments in P301S mice without inducing neurotoxicity or seeding amyloid aggregation. EXP NEUROL. 2023 Apr;362:114346 WB,IHC ; Mouse.
[IF=4.362] WB, IHC ; Mouse.
[IF=4.362] Zhang Yan-hui. et al. α-Lipoic Acid Maintains Brain Glucose Metabolism via BDNF/TrkB/HIF-1α Signaling Pathway in P301S Mice. Front Aging Neurosci. 2020 Aug;12:262 WB ; Mouse.
[IF=3.871] Pengli Wang. et al. The AT1 receptor autoantibody causes hypoglycemia in fetal rats via promoting the STT3A-GLUT1-glucose uptake axis in liver. Mol Cell Endocrinol. 2020 Dec;518:111022 WB,IF,IHC ; Rat.
[IF=3.479] Pérez-Arana, Gonzalo-Martín. et al. Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass. OBES SURG. 2022 Oct;:1-10 IF ; Rat.
[IF=2.447] Xuejun Dai. et al. Comparison of the differentiation abilities of bone marrow?derived mesenchymal stem cells and adipose?derived mesenchymal stem cells toward nucleus pulposus?like cells in three?dimensional culture. Exp Ther Med. 2021 Sep;22(3):1-9 WB ; Rat.
|
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 生長因子和激素 轉(zhuǎn)運蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Rat (predicted: Mouse,Pig,Sheep,Cow,Dog) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 54 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞膜 細胞外基質(zhì) |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human GLUT1: 401-492/492 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | Preservative: 0.02% Proclin300, Constituents: 1% BSA, 0.01M PBS, pH7.4. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a major glucose transporter in the mammalian blood-brain barrier. Mutations in this gene have been found in a family with paroxysmal exertion-induced dyskinesia. [provided by RefSeq, Jul 2008]. Function: Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. Subcellular location is at Cell membrane; multi-pass membrane protein. Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. Subcellular Location: Cell membrane; Multi-pass membrane protein. Melanosome. Note=Localizes primarily at the cell surface. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Tissue Specificity: Expressed at variable levels in many human tissues. Post-translational modifications: Phosphorylated upon DNA damage, probably by ATM or ATR. DISEASE: Defects in SLC2A1 are the cause of GLUT1 deficiency syndrome type 1 (GLUT1DS1) [MIM:606777]; also known as blood-brain barrier glucose transport defect. A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe mental retardation. Defects in SLC2A1 are the cause of GLUT1 deficiency syndrome type 2 (GLUT1DS2) [MIM:612126]. A clinically variable disorder characterized primarily by onset in childhood of paroxysmal exercise-induced dyskinesia. The dyskinesia involves transient abnormal involuntary movements, such as dystonia and choreoathetosis, induced by exercise or exertion, and affecting the exercised limbs. Some patients may also have epilepsy, most commonly childhood absence epilepsy. Mild mental retardation may also occur. In some patients involuntary exertion-induced dystonic, choreoathetotic, and ballistic movements may be associated with macrocytic hemolytic anemia. Similarity: Belongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family. Glucose transporter subfamily. SWISS: P11166 Gene ID: 6513 Database links: Entrez Gene: 6513 Human Entrez Gene: 20525 Mouse Omim: 138140 Human SwissProt: P11166 Human SwissProt: P17809 Mouse Unigene: 473721 Human Unigene: 721551 Human Unigene: 21002 Mouse Unigene: 3205 Rat |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded (Rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Glucose transporter type 1; GLUT1) Polyclonal Antibody, Unconjugated (bs-20173R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
